CommercialCoverageMedium impact
07.06.03c, Bioimpedance for the Detection of Lymphedema
Independence Blue Cross·Oncology, General Surgery, Physical Therapy +3 more·Medical Policy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has changed bioimpedance spectroscopy (CPT 93702) coverage status from Experimental/Investigational to Medically Necessary for lymphedema diagnosis confirmation and surveillance in specific clinical scenarios. Two ICD-10 diagnosis codes (I89.0, I97.2) have been added to the policy. Billing teams must update systems to recognize this service as a covered benefit effective 11/17/2025.
Action Required
By November 17, 2025: Billing team must update billing software and claim submission processes to reclassify CPT 93702 (Bioimpedance spectroscopy for lymphedema assessment) from non-covered/experimental to covered under medical benefits for Independence Blue Cross commercial plans. Update claim edits to accept claims with ICD-10 diagnosis codes I89.0 or I97.2 when submitted with CPT 93702. Educate providers and front desk staff that prior authorization is no longer required for this service when medical necessity criteria are met (asymptomatic patients with lymphatic system impairment history where testing guides early intervention, or symptomatic patients with failed conservative therapy where testing guides escalation). Ensure all claim documentation requirements are met per policy section (medical records reflecting medical necessity must be available for audit upon request). Failure to update billing rules may result in inappropriate claim denials or delays.